Key Inclusion Criteria:
Inclusion Criteria for Non-Pustular Palmoplantar Psoriasis
- Men and women diagnosed with stable plaque psoriasis with involvement of the
palm(s)and/or sole(s) for at least 6 months or more. Stable psoriasis is defined as no
morphology changes or significant flares of disease activity in the opinion of the
investigator.
- Moderate-to-severe plaque psoriasis defined as s-PGA score of ≥ 3 on a 5-point scale
at both screening visit and Day 1.
- Moderate-to-severe non-pustular PP psoriasis, defined as pp-PGA score of ≥ 3 on a
5-pointscale and pp-PASI ≥ 8 at both screening visit and Day 1.
- A total maximum of 5 sterile pustules across both palms and soles limited only to
psoriatic plaques will be allowed.
- Evidence of typical plaque psoriasis outside palms and soles at both screening visit
and Day 1.
- Deemed by the investigator to be a candidate for phototherapy or systemic therapy.
- Failed to respond to, or intolerant of ≥ 1 topical therapy.
Inclusion Criteria for Genital Psoriasis
- Men and women diagnosed with stable plaque psoriasis with involvement of the genital
area for at least 6 months or more. Stable psoriasis is defined as no morphology
changes or significant flares of disease activity in the opinion of the investigator.
- Moderate-to-severe plaque psoriasis defined as s-PGA score of ≥ 3 on a 5-point scale
at both screening visit and Day 1.
- Moderate-to-severe GenPs, defined as static Physician's Global Assessment of Genitalia
(s-PGA-G) score of ≥ 3 on a 6-point scale at both screening visit and Day 1.
- Evidence of typical plaque psoriasis in a non-genital area at both screening visit and
Day 1.
- Deemed by the investigator to be a candidate for phototherapy or systemic therapy.
- Failed to respond to, or intolerant of ≥ 1 topical therapy.
Key Exclusion Criteria:
Target Disease Exceptions
- Has non-plaque psoriasis (for PP pustulosis, PP pustular psoriasis, isolated pustules
on palms or soles with or without erythema outside psoriatic plaques, guttate,
pustular, erythrodermic, and drug-induced psoriasis) at screening or Day 1.
Other protocol-defined inclusion/exclusion criteria apply.
Recruiting
